Pharmaceutical giant GSK is planning to research whether, as a scientific paper published earlier this week suggests, its meningitis B vaccine offers some protection against gonorrhea.
What form the work will take and how quickly it will happen isn’t yet clear; it’s still early days, a buoyant Rino Rappuoli, chief scientist for GSK Vaccines, told STAT in an interview.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Any gonorrhea vaccine will not be 100% reliable. Better to give yourself 1.2 million units of Procaine Penicillin G in each thigh before you go out with a new date. Will also cover you for syphillis.